> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Panel to Review Alkermes Depression NDA
- URL: https://www.fdaweb.com/joint-panel-to-review-alkermes-depression-nda/
- Published: 2018-09-21T12:00:00.000Z
- Updated: 2026-09-15T00:33:31.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142413

*Federal Register* notice: FDA has announced an 11/1 joint Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting. Panel members are scheduled to review an Alkermes NDA for buprenorphine and samidorphan sublingual tablets, indicated as an adjunctive treatment of major depressive disorder. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-20571.pdf?ref=fdaweb.com).